Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Date
2023-04-20ICR Author
Author
Ng, KW
Boumelha, J
Enfield, KSS
Almagro, J
Cha, H
Pich, O
Karasaki, T
Moore, DA
Salgado, R
Sivakumar, M
Young, G
Molina-Arcas, M
de Carné Trécesson, S
Anastasiou, P
Fendler, A
Au, L
Shepherd, STC
Martínez-Ruiz, C
Puttick, C
Black, JRM
Watkins, TBK
Kim, H
Shim, S
Faulkner, N
Attig, J
Veeriah, S
Magno, N
Ward, S
Frankell, AM
Al Bakir, M
Lim, EL
Hill, MS
Wilson, GA
Cook, DE
Birkbak, NJ
Behrens, A
Yousaf, N
Popat, S
Hackshaw, A
TRACERx Consortium,
CAPTURE Consortium,
Hiley, CT
Litchfield, K
McGranahan, N
Jamal-Hanjani, M
Larkin, J
Lee, S-H
Turajlic, S
Swanton, C
Downward, J
Kassiotis, G
Type
Journal Article
Metadata
Show full item recordAbstract
B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS)1,2. Although TLS have been found to correlate with improved patient survival and response to immune checkpoint blockade (ICB), the underlying mechanisms of this association remain elusive1,2. Here we investigate lung-resident B cell responses in patients from the TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) and other lung cancer cohorts, and in a recently established immunogenic mouse model for lung adenocarcinoma3. We find that both human and mouse lung adenocarcinomas elicit local germinal centre responses and tumour-binding antibodies, and further identify endogenous retrovirus (ERV) envelope glycoproteins as a dominant anti-tumour antibody target. ERV-targeting B cell responses are amplified by ICB in both humans and mice, and by targeted inhibition of KRAS(G12C) in the mouse model. ERV-reactive antibodies exert anti-tumour activity that extends survival in the mouse model, and ERV expression predicts the outcome of ICB in human lung adenocarcinoma. Finally, we find that effective immunotherapy in the mouse model requires CXCL13-dependent TLS formation. Conversely, therapeutic CXCL13 treatment potentiates anti-tumour immunity and synergizes with ICB. Our findings provide a possible mechanistic basis for the association of TLS with immunotherapy response.
Collections
Subject
Animals
Humans
Mice
Adenocarcinoma of Lung
Carcinoma, Non-Small-Cell Lung
Disease Models, Animal
Endogenous Retroviruses
Immunotherapy
Lung
Lung Neoplasms
Tumor Microenvironment
B-Lymphocytes
Cohort Studies
Antibodies
Research team
Convergence SC Management
Lung Cancer Group
Language
eng
Date accepted
2023-01-30
License start date
2023-04-20
Citation
Nature, 2023, 616 (7957), pp. 563 - 573
Publisher
NATURE PORTFOLIO